Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma.

Manuela KrumbholzJohanna EiblwieserAndreas RanftJakob ZierkChristian SchmidkonzAdrian M StützPeter Peneder Eleni M TomazouAbbas AgaimyTobias BäuerleWolfgang HartmannUta DirksenMarkus Metzler

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

ctDNA copy number in the plasma of patients with EWS is a quantifiable parameter for early risk stratification and can be used as a dynamic noninvasive biomarker for early prediction of treatment response and outcome of patients.

Keyphrases

copy number
end stage renal disease
mitochondrial dna
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
gene expression
patient reported outcomes